NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Cyient DLM's Q4FY26 Performance Disappoints, But Strong Order Book Offers Hope for Recovery-Led Growth in FY27

Prabhudas Lilladher's research report on Cyient DLM has highlighted a soft performance in Q4FY26, marked by a contraction in margins. Despite this setback, the company has recorded an impressive order book of Rs24.2bn and a healthy book-to-bill ratio, providing strong revenue visibility for the future.

The company's Q4 revenues were impacted by geopolitical disruptions in West Asia, supply chain delays, and pending customer approvals. However, a part of this is expected to be recognized in FY27, offering a glimmer of hope for the company's prospects. Cyient DLM remains well-positioned for a recovery-led growth in FY27, backed by strong order momentum and structural demand tailwinds across key segments.

Revenue and Earnings Estimates

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Our estimates for Cyient DLM's performance over the next two years (FY26-28E) suggest a compound annual growth rate (CAGR) of 30.0% for revenue, 30.5% for EBITDA, and 29.2% for PAT. However, we expect the EBITDA margin to remain flat. In light of this, we have cut our earnings estimates by 13.6% for FY27E and tweaked our estimates for FY28 mainly due to lower growth in revenue.

Ratings and Target Price

Following the uptick in share prices, we have downgraded our rating on Cyient DLM to 'HOLD' from Accumulate. Our target price for the company stands at Rs370, which is higher than our previous estimate of Rs327. This revised target price is based on 24x Mar'28 earnings.

Financial MetricFY26EFY27EFY28E
Revenue Growth30.0%
EBITDA Growth30.5%
PAT Growth29.2%
EBITDA MarginFlat

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Investor Takeaway

Maintain hold rating and target price of Rs 370 for Cyient DLM.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.